Menu Search
Equities

Hisamitsu Pharmaceutical Co Inc

4530:TYO

Hisamitsu Pharmaceutical Co Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,277.00
  • Today's Change-7.00 / -0.16%
  • Shares traded91.70k
  • 1 Year change-6.84%
  • Beta0.8755
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The one analyst offering a 12 month price target expects Hisamitsu Pharmaceutical Co Inc share price to rise to 4,500.00 in the next year from the last price of 4,277.00.
High5.2%4,500.00
Med5.2%4,500.00
Low5.2%4,500.00

Dividends in JPY

In 2024, Hisamitsu Pharmaceutical Co Inc reported a dividend of 85.00 JPY, which represents a 1.19% increase over last year. The analyst covering the company expects dividends of 90.00 JPY for the upcoming fiscal year, an increase of 5.88%.
Div growth (TTM)1.19%
More ▼

Earnings history & estimates in JPY

On Oct 10, 2024, Hisamitsu Pharmaceutical Co Inc reported 2nd quarter 2025 earnings of 58.77 per share.
The next earnings announcement is expected on Apr 09, 2025.
Average growth rate+22.23%
Hisamitsu Pharmaceutical Co Inc reported annual 2024 earnings of 181.62 per share on Apr 11, 2024.
Average growth rate+0.49%
More ▼

Revenue history & estimates in JPY

Hisamitsu Pharmaceutical Co., Inc. had 2nd quarter 2025 revenues of 39.65m. This was 23.52% above the prior year's 2nd quarter results.
Average growth rate+3.51%
Hisamitsu Pharmaceutical Co., Inc. had revenues for the full year 2024 of 141.71m. This was 10.42% above the prior year's results.
Average growth rate+0.84%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.